Supplementary Information

Erythropoietin for Cognitive Deficits Associated with Schizophrenia, Bipolar Disorder, and Major Depression: A Systematic Review

Authors
Xian-Bin Li¹, Wei Zheng², Yu-Ping Ning², Dong-Bin Cai³, Xin-Hu Yang², Gabor S. Ungvari⁴,⁵, Chee H. Ng⁶, Chuan-Yue Wang¹**, Yu-Tao Xiang⁷*†

Affiliations
1Department of Psychiatry, Beijing Key Laboratory of Mental Disorders, Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
2The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
3Faculty of Traditional Chinese Medicine, the First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China
4The University of Notre Dame Australia/Marian Centre, Perth, Australia
5School of Psychiatry & Clinical Neurosciences, University of Western Australia, Perth, Australia
6Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia
7Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China
Correspondence
*Dr. Yu-Tao Xiang
3/F, Building E12
Faculty of Health Sciences
University of Macau
Avenida da Universidade
Taipa, Macau SAR
China
xyutly@gmail.com

**Dr. Chuan-Yue Wang
5 Ankang lane
Deshengmenwai avenue
Xicheng district
Beijing
China
wcymanu@163.com
### Table S1. Risk of bias

<table>
<thead>
<tr>
<th></th>
<th>Random sequence generation (selection bias)</th>
<th>Allocation concealment (selection bias)</th>
<th>Blinding of participants and personnel</th>
<th>Blinding of outcome assessment (symptom reduction, response)</th>
<th>Incomplete outcome data addressed (attrition bias)</th>
<th>Selective reporting (reporting bias)</th>
<th>Other sources of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ehrenreich 2007 (Germany)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
</tr>
<tr>
<td>Miskowiak 2009 (UK)</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
</tr>
<tr>
<td>Miskowiak 2014 (Denmark) (BD)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
</tr>
<tr>
<td>Miskowiak 2014 (Denmark) (TRD)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
</tr>
</tbody>
</table>

+ : how risk of bias; - : high risk of bias; ? : unclear risk of bias; BD: bipolar disorder; TRD: treatment-resistant depression
### Table S2. Adverse drug reactions (ADRs)

<table>
<thead>
<tr>
<th>ADRs</th>
<th>EPO</th>
<th>Pbo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (% in 87 total)</td>
<td>n (% in 89 total)</td>
</tr>
<tr>
<td>Acute suicide risk</td>
<td>1 (1.1)</td>
<td>1 (1.1)</td>
</tr>
<tr>
<td>Increased thrombocytes (&gt;4×10^9/L)</td>
<td>3 (6.9)</td>
<td>1 (1.1)</td>
</tr>
<tr>
<td>Need of bloodletting</td>
<td>4 (4.6)</td>
<td>1 (1.1)</td>
</tr>
</tbody>
</table>

EPO: erythropoietin; Pbo: placebo
Figure S1: Flow diagram

Records identified through electronic search (n=680)

Additional records identified through hand search (n=0)

Records after duplicates removed (n=58)

Records screened (n=622)

Records excluded based on title and abstract (n=601)

Full-text articles excluded (n=17):
- Wrong population (n=1)
- Study protocol (n=1)
- Reviews (n=2)
- Data from prior published trials (n=9)
- Others (n=4)

Full-text articles assessed for eligibility (n=21)

Studies included in qualitative synthesis (n=4)